Interview with Janssen’s Dr Amrit Ray: One Company’s Efforts To Bring Order To The Challenging Area of Compassionate Use

 
• By Sukaina Virji
  
Generate a summary of this article
Listen to this article
Beta

Where do you go? Who do you ask? What’s the policy? Compassionate use programs can be hard for patients to navigate. And for the companies who run them, they’re often very challenging to manage. Janssen is one company that is trying to introduce some order.

In 2015, Johnson & Johnson announced a first-of-its-kind pilot partnership between its pharma unit Janssen and the Division of Medical Ethics at the New York University (NYU) School of Medicine. The partnership involved the Compassionate Use Advisory Committee (CompAC), a panel of external bioethical experts, physicians and patient representatives convened by NYU, examining US-based requests for compassionate use of Janssen’s investigational drugs and making recommendations as to who would most benefit from such use. The project has been a success and could act as a model for other companies, says Janssen's Chief Medical Officer Dr Amrit Ray. However, as Ray explained to Sukaina Virji*, there is still much to learn in this area, and the initiative has not been without its ethical dilemmas along the way.

The Takeaways, Part One – Dr Amrit Ray on Janssen’s efforts to bring order to compassionate use

  • In compassionate use, historically, it's not been clear where to go, who to ask, how to ask, what the process and policies will be, and that's led to a lot of inconsistency for patients,
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Nielsen Hobbs

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Test H1 Heading

Test H1 Story

Shape Our Content: Take The Reader Survey

 
• By Nielsen Hobbs

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

More from Pink Sheet

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By Sue Sutter

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 
• By Derrick Gingery

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.

PinkSheet-R&D-Free: ‘Ranking’ article that includes different Composer content

 
• By Nabil, Olga Zviezdicheva, Reed Miller, Mary Jo Laffler, Ian Schofield, João Andrés-Ruíz de la Fontaine-LeBlanc, Chloë Anastasía-Stojanović del Castillo-Ribeirão, and Nabil

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.